I finally got a chance to look at the 10Q.
During the quarter ending 9/30, they purchased "127,000 shares at an aggregate purchase price of $2,175,218, representing an average price of $17.128 per share. Through November 13, 1998, the Company had purchased an aggregate of 415,300 shares of Common Stock under the stock buyback program at an aggregate purchase price of $7,484,278, representing an average purchase price of $18.021 per share."
I was a little worried that they did have other drugs in the pipeline, but now I feel better: "The Company's future prospects are substantially dependent on approval by the FDA and the successful commercialization of Vasomax(R)."
On Mexico sales: "There were no product royalties earned for the quarter ended September 30, 1998, due to the product launch loading into the distribution channel in June 1998." I guess this does leave open the possibility of future revenues.
Alan |
